Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221542 · ClinicalTrials.gov registry record · Phase 1
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study of Prostate Cancer, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 479
- Enrollment target
- 20
- Study locations
NCT04221542: Recruiting Phase 1 study of Prostate Cancer, sponsored by Amgen.
NCT04221542 is a Phase 1 study of Prostate Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 479 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04221542, a Phase 1 study of Prostate Cancer, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 479 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 are open to accrual.
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG AMG 509
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- Providence Saint Jude Medical Center - Fullerton
- University of California San Francisco - San Francisco
North Carolina
- Duke University - Durham
- Wake Forest University Health Sciences - Winston-Salem
Pennsylvania
- Thomas Jefferson University - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Colorado
- Rocky Mountain Cancer Centers - Aurora
Connecticut
- Yale New Haven Hospital - New Haven
Georgia
- Emory University - Atlanta
Indiana
- Indiana University - Indianapolis
Kansas
- MidAmerica Cancer Care - Merriam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2020-03-04 |
| Est. Completion | 2032-03-21 |
| Phase | Phase 1 |
What NCT04221542 shows while recruiting
NCT04221542 is an interventional study that assigns participants to a tested intervention. The registered 479 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (21% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Enzalutamide is the first listed.
NCT04221542 names 20 study sites across 16 states, led by California, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04221542 about?
NCT04221542 is a clinical study titled "Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer". The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 ar...
What is the current status of trial NCT04221542?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 479 participants. The study started on 2020-03-04. Estimated completion is 2032-03-21.
What conditions does trial NCT04221542 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT04221542?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone (DRUG), AMG 509 (DRUG).
Who is sponsoring clinical trial NCT04221542?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04221542 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04221542's enrollment target sits among peer trials
479 119th of 735 higher than 617 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI